237 related articles for article (PubMed ID: 31991537)
1. Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation.
Date Y; Ito K
Mol Cells; 2020 Feb; 43(2):176-181. PubMed ID: 31991537
[TBL] [Abstract][Full Text] [Related]
2.
Ito K; Otani S; Date Y
Cells; 2023 Apr; 12(8):. PubMed ID: 37190031
[TBL] [Abstract][Full Text] [Related]
3. C/ebpα represses the oncogenic Runx3-Myc axis in p53-deficient osteosarcoma development.
Omori K; Otani S; Date Y; Ueno T; Ito T; Umeda M; Ito K
Oncogene; 2023 Aug; 42(33):2485-2494. PubMed ID: 37402881
[TBL] [Abstract][Full Text] [Related]
4. RUNX3 and p53: How Two Tumor Suppressors Cooperate Against Oncogenic Ras?
Lee JW; van Wijnen A; Bae SC
Adv Exp Med Biol; 2017; 962():321-332. PubMed ID: 28299666
[TBL] [Abstract][Full Text] [Related]
5. Functional relationship between p53 and RUNX proteins.
Bae SC; Kolinjivadi AM; Ito Y
J Mol Cell Biol; 2019 Mar; 11(3):224-230. PubMed ID: 30535344
[TBL] [Abstract][Full Text] [Related]
6.
Lee YS; Lee JY; Song SH; Kim DM; Lee JW; Chi XZ; Ito Y; Bae SC
Mol Cells; 2020 Oct; 43(10):889-897. PubMed ID: 33115981
[No Abstract] [Full Text] [Related]
7. RUNX3 is oncogenic in natural killer/T-cell lymphoma and is transcriptionally regulated by MYC.
Selvarajan V; Osato M; Nah GSS; Yan J; Chung TH; Voon DC; Ito Y; Ham MF; Salto-Tellez M; Shimizu N; Choo SN; Fan S; Chng WJ; Ng SB
Leukemia; 2017 Oct; 31(10):2219-2227. PubMed ID: 28119527
[TBL] [Abstract][Full Text] [Related]
8. Runx3 is required for oncogenic Myc upregulation in p53-deficient osteosarcoma.
Otani S; Date Y; Ueno T; Ito T; Kajikawa S; Omori K; Taniuchi I; Umeda M; Komori T; Toguchida J; Ito K
Oncogene; 2022 Jan; 41(5):683-691. PubMed ID: 34803166
[TBL] [Abstract][Full Text] [Related]
9. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.
Lau QC; Raja E; Salto-Tellez M; Liu Q; Ito K; Inoue M; Putti TC; Loh M; Ko TK; Huang C; Bhalla KN; Zhu T; Ito Y; Sukumar S
Cancer Res; 2006 Jul; 66(13):6512-20. PubMed ID: 16818622
[TBL] [Abstract][Full Text] [Related]
10. Tumor suppressor activity of RUNX3.
Bae SC; Choi JK
Oncogene; 2004 May; 23(24):4336-40. PubMed ID: 15156190
[TBL] [Abstract][Full Text] [Related]
11. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination.
Chi XZ; Kim J; Lee YH; Lee JW; Lee KS; Wee H; Kim WJ; Park WY; Oh BC; Stein GS; Ito Y; van Wijnen AJ; Bae SC
Cancer Res; 2009 Oct; 69(20):8111-9. PubMed ID: 19808967
[TBL] [Abstract][Full Text] [Related]
12. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors.
Chuang LS; Ito Y
Oncogene; 2010 May; 29(18):2605-15. PubMed ID: 20348954
[TBL] [Abstract][Full Text] [Related]
13. Context-dependent activation of Wnt signaling by tumor suppressor RUNX3 in gastric cancer cells.
Ju X; Ishikawa TO; Naka K; Ito K; Ito Y; Oshima M
Cancer Sci; 2014 Apr; 105(4):418-24. PubMed ID: 24447505
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic Runx1-Myc axis in p53-deficient thymic lymphoma.
Date Y; Taniuchi I; Ito K
Gene; 2022 Apr; 819():146234. PubMed ID: 35114276
[TBL] [Abstract][Full Text] [Related]
15. RUNX3 interactome reveals novel centrosomal targeting of RUNX family of transcription factors.
Chuang LS; Lai SK; Murata-Hori M; Yamada A; Li HY; Gunaratne J; Ito Y
Cell Cycle; 2012 May; 11(10):1938-47. PubMed ID: 22544322
[TBL] [Abstract][Full Text] [Related]
16. Runx3 and Cell Fate Decisions in Pancreas Cancer.
Whittle MC; Hingorani SR
Adv Exp Med Biol; 2017; 962():333-352. PubMed ID: 28299667
[TBL] [Abstract][Full Text] [Related]
17. Role of RUNX3 in bone morphogenetic protein signaling in colorectal cancer.
Lee CW; Ito K; Ito Y
Cancer Res; 2010 May; 70(10):4243-52. PubMed ID: 20442291
[TBL] [Abstract][Full Text] [Related]
18. Runx3 Restoration Regresses K-Ras-Activated Mouse Lung Cancers and Inhibits Recurrence.
Lee JY; Lee JW; Park TG; Han SH; Yoo SY; Jung KM; Kim DM; Lee OJ; Kim D; Chi XZ; Kim EG; Lee YS; Bae SC
Cells; 2023 Oct; 12(20):. PubMed ID: 37887282
[TBL] [Abstract][Full Text] [Related]
19. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
20. Runx3 at the interface of immunity, inflammation and cancer.
Lotem J; Levanon D; Negreanu V; Bauer O; Hantisteanu S; Dicken J; Groner Y
Biochim Biophys Acta; 2015 Apr; 1855(2):131-43. PubMed ID: 25641675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
